UBS AM
ODT

UBS AM’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

UBS AM’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,800
Closed -$47.2K – 2793
2021
Q1 		$47.2K Buy
13,800
+1,400
+11% +$26.5K ﹤0.01% 2593
2020
Q4 		$238K Buy
+12,400
New +$191K ﹤0.01% 2468

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS AM's ODT Position: Q2 2021 in Review

UBS AM sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q2 2021, closing a stake of 13,800 shares — an estimated $47.2K sold.

UBS AM first reported a position in ODT in Q4 2020 and held it in 2 quarters. The position peaked at $238K in Q4 2020. 69 funds tracked by Wall St. Rank hold ODT as of Q2 2021.

  • UBS AM reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • UBS AM sold 13,800 Odonate Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $47.2K.
  • UBS AM first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • UBS AM's Odonate Therapeutics, Inc. Common Stock position peaked at $238K in Q4 2020.
  • 69 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q2 2021.

Based on UBS AM's 13F filing for Q2 2021, filed 16 Aug 2021.